Secarna Pharmaceuticals GmbH & Co. KG, of Marburg, Germany, inked a co-development agreement with Firebrand Therapeutics Inc., of Princeton, N.J., designed to leverage Secarna's locked nucleic acid, or LNAplus, platform to pursue targets that play important roles in cancer metastasis and Firebrand's expertise in molecular biology, genomics and computational biology approaches.